Herborium Group, Inc. (OTCMKTS:HBRM) has just recorded its 9th consecutive quarter double digit sales growth. The company recently released its 1Q2015, reporting an increase in sales by 21%. HBRM officials attributed the increase to expansion of sales in France and UK. They also said that international orders are 20% higher than domestic ones and also give a higher margin. Additionally, the company had also launched a dedicated French platform for its lead product, AcnEase. The platform helped the company target more sales in the region. The company has also added mobile platforms to the marketing strategy, where the French platform for AcnEase accounts for 25% of total sales.
HBRM plans to use this opportunity to initiate its development and up listing plan that it had outlined in at the start of the year. Herborium focuses on developing botanical therapeutics and now it plans to extend its product line. The company is seeking new partnerships to expand globally and tap into profitable markets for AcnEase. The partnerships would include co-marketing arrangements to enter growing markets, with a focus on Asia. The product itself has shown a lot of promise, by showing a 96% success rate in effectively treating acne. It is known that around 75% of all people have acne sometime in their lives, so the potential is definitely huge.
The product has also shown great promise in cases of adult hormonal acne, which is one of the toughest to treat. This industry was lacking the presence of an effective drug recently, after the withdrawal of Accutane, due to health concerns. AcnEase enjoys the benefit of being an all natural drug, with an excellent health profile. The acne treatment market is considered to be worth $4 billion. The rate of growth of skin conditions is 11%, which will also increase the industry value.
Herborium Group, Inc. (OTCMKTS:HBRM) closed at $0.00010, reporting no change on April 15. The company currently trades 75.67 million shares in the market, with a 52-week range of $0.00-$0.10.
